Verastem reports additional Phase III data for duvelisib in CLL

Verastem Inc. (NASDAQ:VSTM) reported additional data from the Phase III DUO trial evaluating duvelisib (IPI-145) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data were presented at the American Society of

Read the full 384 word article

User Sign In